Trial reportNeuroImage2023
Optimizing quantification of MK6240 tau PET in unimpaired older adults.
Trial report in NeuroImage, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 14 citations in OpenAlex.
- Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention: The POINTER Imaging Ancillary Study.JAMA neurology · 2026Trial
- Baseline characteristics of the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER): Successful enrollment of a diverse clinical trial cohort at risk for cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Brain structure in the cingulate cortex and locus coeruleus in late life is associated with engagement in complex mental activities across the life span.Neurobiology of aging · 2026Article
- Associations of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Measuring in-vivo tau pathology in the basal forebrain with PET imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Are the factors associated with cognitive performance generalizable across cohorts?NeuroImage. Clinical · 2026Article
- Plasma p-tau217 as a two-cutoff approach to improve tau-PET screening and trial recruitment in Alzheimer's disease.Scientific reports · 2026Article
- Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in females.European journal of nuclear medicine and molecular imaging · 2026Article
- Dissociable Mechanisms Underlie Differences Between Memory and Metamemory in Older Adults: The Differentiating Role of Anxiety and Depression Symptoms.Hippocampus · 2026Article
- Evaluation of [Acta neuropathologica communications · 2026Article
- Development and Implementation of a Radiation Safety Screening Protocol for a Clinical Study Using Amyloid Positron Emission Tomography Imaging.Ochsner journal · 2026Article
- Highly specific amyloid and tau PET ligands for ATN classification in suspected Alzheimer's disease patients.Annals of nuclear medicine · 2025Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- In Vivo Head-to-Head Comparison of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Bioinformatics and experimental validation identify biomarkers for diagnosing Alzheimer's disease.Frontiers in aging neuroscience · 2025Article
- Positron emission tomography harmonization in the Alzheimer's Disease Neuroimaging Initiative: A scalable and rigorous approach to multisite amyloid and tau quantification.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Evaluating the effect of extra-cerebral off-target binding in [F-18]MK6240 PET scans in early-stage Alzheimer's disease.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- MRI-free processing of tau PET images for early detection.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Tau positron emission tomography in patients with cognitive impairment and suspected Alzheimer's disease.Fukushima journal of medical science · 2023Article
- Development, initial validation, and application of a visual read method for [Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 12 institutions in 1 country.
Funding
Abstract
Accurate measurement of Alzheimer's disease (AD) pathology in older adults without significant clinical impairment is critical to assessing intervention strategies aimed at slowing AD-related cognitive decline. The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (POINTER) is a 2-year randomized controlled trial to evaluate the effect of multicomponent risk reduction strategies in older adults (60-79 years) who are cognitively unimpaired but at increased risk for cognitive decline/dementia due to factors such as cardiovascular disease and family history. The POINTER Imaging ancillary study is collecting tau-PET ([
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.